

***Fiscal Year 2021 (FY21) Department of Defense (DOD) Orthotics and Prosthetics Outcomes Research Program (OPORP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p><b>Clinical Research Award (CRA)</b> Go to:</p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-21-OPORP-CRA</p>	<ul style="list-style-type: none"> <li>• Independent investigators at all academic levels (or equivalent)</li> </ul>	<ul style="list-style-type: none"> <li>• Supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to Service Members, Veterans, and other individuals with limb loss and/or limb impairment.</li> <li>• Supported research is intended to generate clinically useful evidence with potential to enhance and optimize patient outcomes, and inform clinical or policy decisions.</li> <li>• Multidisciplinary collaboration among academia, industry, patient advocacy, the military Services, the Department of Veterans Affairs (VA), and/or other federal government agencies is highly encouraged.</li> <li>• Applications submitted to the FY21 OPORP CRA must address at least one of the FY21 OPORP Focus Areas.</li> <li>• Preclinical studies using animals are <i>not</i> allowed.</li> <li>• Clinical trials are <i>not</i> allowed.</li> </ul>	<p>The FY21 OPORP CRA offers two funding levels:</p> <p><b>Funding Level 1:</b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$350,000</b> for total costs (direct costs plus indirect costs)</li> <li>• Maximum period of performance is <b>2</b> years</li> </ul> <p><b>Funding Level 2:</b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$2,000,000</b> for total costs (direct costs plus indirect costs)</li> <li>• Maximum period of performance is <b>4</b> years</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 15, 2021 5:00 p.m. Eastern time</p> <p><b>Application:</b> July 29, 2021 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p><b>Clinical Trial Award (CTA)</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-21-OPORP-CTA</p>	<ul style="list-style-type: none"> <li>• Independent investigators at all academic levels (or equivalent)</li> </ul>	<ul style="list-style-type: none"> <li>• Supports implementation of clinical trials with the potential to have a significant impact on improving the health and well-being of Service Members and military beneficiaries, Veterans, and other individuals with limb loss and/or limb impairment.</li> <li>• Supports clinical trials that evaluate orthoses and/or prostheses using patient-centric outcomes for the purpose of generating clinically useful evidence to enhance and optimize patient outcomes.</li> <li>• Multidisciplinary collaboration among academia, industry, patient advocacy, the military Services, VA, and/or other federal government agencies is highly encouraged.</li> <li>• Applications submitted to the FY21 OPORP CTA must address at least one of the FY21 OPORP Focus Areas.</li> <li>• Preclinical studies using animals are <i>not</i> allowed.</li> </ul>	<p>The FY21 OPORP CTA offers two funding levels:</p> <p><b>Funding Level 1:</b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$350,000</b> for total costs (direct costs plus indirect costs)</li> <li>• Maximum period of performance is <b>3</b> years</li> </ul> <p><b>Funding Level 2:</b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$4,000,000</b> for total costs (direct costs plus indirect costs)</li> <li>• Maximum period of performance is <b>4</b> years</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 15, 2021 5:00 p.m. Eastern time</p> <p><b>Application:</b> July 29, 2021 11:59 p.m. Eastern time</p>